Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) insider David P. Rosenbaum sold 5,312 shares of Ardelyx stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $6.26, for a total value of $33,253.12. Following the transaction, the insider now directly owns 153,616 shares of the company’s stock, valued at approximately $961,636.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Ardelyx Trading Down 1.1 %
NASDAQ ARDX opened at $6.15 on Wednesday. The company has a quick ratio of 3.99, a current ratio of 4.21 and a debt-to-equity ratio of 0.68. The stock’s 50-day simple moving average is $5.87 and its two-hundred day simple moving average is $6.71. Ardelyx, Inc. has a twelve month low of $3.16 and a twelve month high of $10.13. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -21.96 and a beta of 0.90.
Ardelyx (NASDAQ:ARDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $73.20 million for the quarter, compared to analysts’ expectations of $55.03 million. Ardelyx had a negative return on equity of 39.73% and a negative net margin of 31.02%. Ardelyx’s revenue for the quarter was up 228.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.08) EPS. Research analysts forecast that Ardelyx, Inc. will post -0.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Ardelyx
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its holdings in shares of Ardelyx by 1,026.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,233 shares during the last quarter. HighMark Wealth Management LLC bought a new position in shares of Ardelyx during the first quarter valued at about $36,000. Redwood Wealth Management Group LLC bought a new position in shares of Ardelyx during the second quarter valued at about $62,000. Jump Financial LLC purchased a new position in shares of Ardelyx in the fourth quarter worth about $63,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Ardelyx in the 1st quarter valued at about $64,000. 58.92% of the stock is owned by hedge funds and other institutional investors.
About Ardelyx
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Recommended Stories
- Five stocks we like better than Ardelyx
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Differences Between Momentum Investing and Long Term Investing
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Are Dividends? Buy the Best Dividend Stocks
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.